2.1
Talazoparib (Talzenna, Pfizer) is indicated 'in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated'.
2 Information about talazoparib with enzalutamide
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for talazoparib with enzalutamide.
Price
2.3
The list price of talazoparib is £1,655 for a 30-pack of 0.10 mg or 0.25 mg capsules (excluding VAT; BNF online accessed January 2026). The list price of enzalutamide is £2,734.67 for a 112‑pack of 40 mg tablets (excluding VAT; BNF online accessed January 2026).
2.4
Pfizer has a commercial arrangement for talazoparib. This makes talazoparib available to the NHS with a discount. The size of the discount is commercial in confidence.
2.5
Astellas has a commercial arrangement for enzalutamide. This makes enzalutamide available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.6
Please see information on Pfizer's Carbon Reduction Plan for UK carbon emissions.